Qilu Pharmaceutical Malay acid Isola tablets through a consistent evaluation of supplementary applications

Medicine Network December 18th, December 16th, the official website of the State Drug Administration shows that Qilu Pharmaceutical's Malay acid Isola tablets through a consistent evaluation of supplementary applications.
Isola tablets for gastric mucous membrane protection agent, Qilu Pharmaceuticals for the first evaluation of the variety of enterprises.
, Qilu Pharmaceuticals has 45 varieties have been evaluated.
is a gastric mucous membrane protection agent, clinically commonly used in the treatment of stomach ulcers.
By strengthening the binding between the epithal cells of the stomach mucosa, it inhibits the peeling, shedding and expansion of the cell gap of the epithern cells, and enhances the stability of the mucous membrane cells themselves, so as to play the role of mucous membrane defense and inhibit the use of harmful substances through the mucous membranes.
is the original research manufacturer for Japan's new pharmaceutical co., Ltd., has been listed in China, the commodity named Gesseron.
there are 5 generic pharmaceutical companies in the domestic market, namely Qilu Pharmaceuticals, Wanyu Pharmaceuticals, Jiangxi Pharmaceuticals, Sanofi, Tianlong Pharmaceuticals.
Malay acid Isola tablet manufacturer Source: Minet MID drug index comprehensive database Minet data show that in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal Isola Ding sales of 14.59 million yuan, Japan New Pharmaceutical Co., Ltd. accounted for 83.37 percent of the market share.
to date, Qilu Pharmaceuticals has 45 varieties (80 product regulations) through/as follows through consistency evaluation.
is also noteworthy that no other generic drug companies have submitted applications for conformity evaluation supplements, nor have any companies submitted applications for listing under the new registration classification.
as the exclusive evaluation enterprise of this variety, Qilu Pharmaceuticals is expected to use the "priority procurement, priority selection" policy to expand the sales market of products.
source: MiNet Database, NMPA